Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase I open-label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose of AUR107 in adults with relapsed advanced malignancies. The study focuses on patients with selected advanced solid tumors, such as non-small cell lung cancer, gastric cancer, urothelial cancer, kidney cancer, colon cancer, and esophageal cancer, who have no curative or life-prolonging treatment options left. This first-in-human trial aims to find the best dose of AUR107 using a traditional dose-escalation design. Participants will receive oral AUR107 once daily at escalating doses ranging from 5 mg to 200 mg. The trial follows a 33 dose escalation design to evaluate safety and determine the optimal biological dose based on safety, pharmacokinetics, and pharmacodynamics data. The study is multicenter and includes dose expansion following dose escalation. During the study, participants will be closely monitored for dose-limiting toxicities and treatment-related adverse events over 28-day cycles. Researchers will measure pharmacokinetic parameters such as maximum concentration, time to maximum concentration, area under the curve, mean residence time, and elimination half-life at various time points under fasting and fed conditions. Safety assessments and clinical evaluations will be conducted throughout the study, which is expected to continue until June 2027.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine AVD in adults with untreated stage 3 or 4 classical Hodgkin Lymphoma. This phase 4 study focuses on how well this combination works and monitors any side effects experienced by participants. The study is open-label and involves patients from India with confirmed Hodgkin Lymphoma. Participants will receive brentuximab vedotin at a dose of 1.2 mgkg through intravenous infusion on days 1 and 15 of each 28-day treatment cycle. Each infusion is given within one hour after receiving doxorubicin, vinblastine, and dacarbazine infusions. This treatment is provided for up to six cycles, lasting about six months in total. During the study, participants will have heart function tested by echocardiography and lung function assessed by pulmonary function tests. Researchers will review safety by tracking adverse events for up to 40 weeks and assess how well the treatment works by measuring remission rates and survival outcomes. After finishing treatment, participants will have a final health check two months later to monitor their status and overall well-being.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining Dato-DXd with rilvegostomig as an additional treatment compared to standard care in adults with high-risk muscle invasive urothelial carcinoma MIUC who have undergone radical surgery. This Phase III trial focuses on participants with residual disease at high risk of recurrence after surgery. The study aims to see if the new combination improves disease-free survival compared to current standard treatments. Participants are randomly assigned to one of three groups Arm 1 receives Dato-DXd plus rilvegostomig intravenously every three weeks for up to one year Arm 2 receives Dato-DXd alone on the same schedule Arm 3 receives standard care, which includes nivolumab, durvalumab, or a combination of enfortumab vedotin and pembrolizumab, given intravenously at intervals ranging from every two to four weeks for up to a year. Treatment duration and dosing can be adjusted based on tolerance and investigator assessment. During the trial, participants will have visits approximately every three weeks or as per standard care schedules, depending on their assigned group, for up to 12 months of treatment. Researchers will monitor disease recurrence and survival outcomes for up to 78 months from the first participants enrollment. Assessments include clinical evaluations and disease status monitoring to measure disease-free survival and overall survival. Participants will be followed closely to assess safety and effectiveness of the treatments over this extended period.
Actively Recruiting
Researchers are evaluating the effectiveness of AZD2265 compared to standard treatments in men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study aims to show whether AZD2265 can improve radiographic progression-free survival and overall survival. This phase III trial involves about 670 adult male participants and is sponsored by AstraZeneca. Participants will be randomly assigned to receive either AZD2265 or a standard care treatment chosen by the investigator, which may include cabazitaxel, androgen receptor pathway inhibitors ARPI, or radium-223. Treatments will continue until the disease progresses, unacceptable side effects occur, or other reasons for stopping arise. Tumor scans will continue after treatment ends until confirmed progression or death. Throughout the study, participants will be monitored with imaging scans and laboratory tests to assess disease progression and response to treatment. Researchers will track multiple outcomes such as progression-free survival, PSA reductions, response rates, and symptomatic skeletal events for up to approximately 33 months. Safety and scientific integrity will be overseen by an independent committee, and participants will be followed for survival until the studys completion.
Actively Recruiting
Researchers are evaluating oral sodium copper chlorophyllin CHL in patients aged 12 to 65 years who are undergoing myeloablative total body irradiation TBI as part of conditioning before their first allogeneic hematopoietic stem cell transplantation HSCT. This Phase II, single-arm study aims to assess whether CHL can reduce the frequency and severity of oral mucositis, a common and painful complication of TBI that affects eating, increases pain medication use, and can lead to longer hospital stays and infections. Participants will receive 750 mg of oral sodium copper chlorophyllin once daily, either as a tablet or oral suspension, starting 48 hours before beginning TBI conditioning and continuing until 28 days after the transplant. Alongside this, they will undergo standard TBI-based conditioning and allogeneic HSCT as part of their routine medical care. The study focuses on the safety and effectiveness of CHL in reducing severe oral mucositis and related treatment toxicities. During the study, participants will have regular clinical assessments to monitor oral mucositis severity, treatment-related side effects, engraftment progress, and graft-versus-host disease. Blood and saliva samples will be collected at set times for analysis of inflammatory markers and drug levels. The primary measure is the occurrence of severe oral mucositis by 28 days post-transplant, with additional outcomes including duration of mucositis, use of nutrition and pain medications, and transplant complications. The total study period extends through 100 days post-transplant for some assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of once-weekly Somatrogon compared to daily Growth Hormone Genotropin for treating children born Small for Gestational Age SGA or with Idiopathic Short Stature ISS. This randomized, open-label study involves pre-pubertal children who have not previously received growth hormone treatment. The study is planned to last 12 months, including a screening period of up to 30 days, and aims to measure growth outcomes in these children. The study includes two groups one with 140 children with SGA and another with 114 children with ISS. Both groups will be randomly assigned to receive either Somatrogon once weekly via a subcutaneous disposable prefilled pen or Genotropin daily subcutaneous injections using commercial growth hormone delivery devices. Treatment will continue for 12 months for all participants. Participants will be involved in regular visits to assess growth through measurements such as annual height velocity, height standard deviation scores, bone maturation, and levels of Insulin-like Growth Factor-1 IGF-1. Quality of life related to health will also be evaluated before and after treatment. Monitoring includes laboratory tests and maintaining stable hormone levels. The total participation duration includes the screening and 12 months of treatment, with assessments at multiple time points throughout the study.
Actively Recruiting
Researchers are studying cervix cancer by using patient data from completed and ongoing clinical trials to develop and validate machine learning tools. The study aims to create knowledge-based systems that improve treatment delivery and help identify patients who may benefit from more intensive treatments. This observational study integrates radiation treatment information, quantitative imaging, and patient outcomes to advance personalized treatment approaches. The research focuses on three main goals. First, automatic delineation of complex tumor targets on MRI and CT scans is performed for various volumes and organs related to cervix cancer. Second, machine learning models are developed to predict normal tissue toxicity using texture analysis and radiation dose maps. Third, the study integrates imaging, staging, pathology, and molecular biology data to predict treatment response and identify high-risk patient groups. Patient data sets include imaging and biomarker information collected during chemoradiation and brachytherapy. Participants existing clinical trial data and imaging are used retrospectively, so no new treatment is given. The research team will generate software tools for automated tumor delineation and develop normal tissue complication plots over three years. They will also identify high-risk patients who might need intensified therapy based on integrated imaging and molecular features. The study includes patients aged 18 to 90 who have completed or are undergoing radiation therapy for cervix cancer. Outcomes measured include software development, toxicity prediction model validation, and risk group identification.
Actively Recruiting
Researchers are evaluating the effect of adding oral rifaximin tablets during allogeneic stem cell transplant ASCT in adults with acute leukemia. This randomized phase II study aims to see if rifaximin can improve the gut microbiome diversity and reduce risks such as death, infections, and graft versus host disease GVHD after transplant. The study also investigates immune system recovery and the impact of gut bacteria on immunity using advanced techniques like single-cell transcriptomics. Participants are randomly assigned to receive either rifaximin 200 mg tablets twice daily from 8 days before transplant to 60 days after, along with standard post-transplant care, or standard care alone. Standard care includes usual anti-GVHD treatments, antibiotics, and transfusions as needed. Stool and blood samples will be collected at various times to study changes in gut bacteria and immune cells, and gut biopsies may be analyzed if performed for GVHD. During the study, participants will have their gut microbial diversity measured about 14 days after transplant. Researchers will also assess outcomes like non-relapse mortality, severe acute GVHD, multidrug-resistant sepsis, and immune recovery over the following months up to one year. Safety and immune profiles will be monitored through blood tests, microbiome sequencing, and possibly tissue analysis. The study is expected to last until 2027, with ongoing evaluations throughout this period.
1-10 of 25
1